1.
[18F]FDG PET immunotherapy radiomics signature (iRADIOMICS) predicts response of non-small-cell lung cancer patients treated with pembrolizumab. Radiol Oncol [Internet]. 2020 Sep. 2 [cited 2026 Nov. 21];54(3):285-94. Available from: https://www.radioloncol.com/index.php/ro/article/view/3452